For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>Sitaxsentan (IPI 1040; TBC 11251) is a selective endothelin A (ETA) receptor antagonist. Antihypertensive. Sitaxsentan is used in treatment of chronic heart failure.<br>IC50 value:<br>Target: ETA receptor</p>
| Catalog Number | I002384 |
| CAS Number | 184036-34-8 |
| Synonyms | N-(4-chloro-3-methylisoxazol-5-yl)-2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophene-3-sulfonamide |
| Molecular Formula | C18H15ClN2O6S2 |
| Purity | ≥95% |
| Target | Endothelin Receptor |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| Reference | <p style=/line-height:25px/> <br>[2]. Chin M, Levy RD, Yoshida EM, Byrne MF.Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.Can Respir J. 2012 Jan-Feb;19(1):e1-2. <br>[3]. Sandoval J, et al. STRIDE-4 investigators.Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.Pulm Pharmacol Ther. 2012 Feb;25(1):33-9. Epub 2011 Nov 2. <br>[4]. Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.Vasc Health Risk Manag. 2011;7:119-24. Epub 2011 Mar 2. <br>[5]. Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1118-23. Epub 2010 Aug 6. </p> |
